StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30508% above fair value
$199.33+2.54 (+1.29%)

Close on Nov 19, 2026Market cap $79.58BP/E –Yield –

Moderna Accrued liabilities by Quarter

Accrued liabilities — External development & clinical/manufacturing operations ($M) ($M)

Moderna Accrued liabilities: $78M in Q2 2026, down 27.8% from a year earlier.

Latest, Q2 2026
78
Period ended Jun 30, 2026
Change on a year earlier
-27.8%
108 in Q2 2025
History
25 quarters
Since Q4 2019
Sources
24
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-07-31) ↗

Reported in Form 10-Q / 10-K Note 8 (Balance Sheet Details).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAccrued liabilities — External development & clinical/manufacturing operations ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202678-27.8%Form 10-Q (filed 2026-07-31) ↗
Q1 2026Mar 31, 202681-32.5%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025106-11.7%Form 10-Q (filed 2026-07-31) ↗
Q3 2025Sep 30, 202594+17.5%Form 10-Q (filed 2025-11-06) ↗
Q2 2025Jun 30, 2025108+20.0%Form 10-Q (filed 2025-08-01) ↗
Q1 2025Mar 31, 2025120-14.9%Form 10-Q (filed 2025-05-01) ↗
Q4 2024Dec 31, 2024120-14.3%Form 10-K (filed 2026-02-20) ↗
Q3 2024Sep 30, 202480-27.3%Form 10-Q (filed 2024-11-07) ↗
Q2 2024Jun 30, 202490-36.6%Form 10-Q (filed 2024-08-01) ↗
Q1 2024Mar 31, 2024141+43.9%Form 10-Q (filed 2024-05-02) ↗
Q4 2023Dec 31, 2023140+59.1%Form 10-K (filed 2025-02-21) ↗
Q3 2023Sep 30, 2023110+14.6%Form 10-Q (filed 2023-11-03) ↗
Q2 2023Jun 30, 2023142+118.5%Form 10-Q (filed 2023-08-03) ↗
Q1 2023Mar 31, 202398+12.6%Form 10-Q (filed 2023-05-04) ↗
Q4 2022Dec 31, 202288-35.8%Form 10-K (filed 2024-02-23) ↗
Q3 2022Sep 30, 202296-23.2%Form 10-Q (filed 2022-11-03) ↗

Breakdown

What makes up accrued liabilities

Cite this data

StockData. (2026). Moderna Accrued liabilities ($M), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/accrued-dev-ops

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.

See a number that looks wrong?